Personal tools

B/BE/99/VW8

Development of a combined live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a sucutaneous administration of a recombinant canarypoxvirus expressing FELV genes.
Company/Institution Merial
Parental organism Canarypoxvirus (ALVAC clone)
Transgene(s) env and gag genes of the type A virus of feline leukemia (FELV)
Treated organism cats
Title of the project Development of a combined live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a sucutaneous administration of a recombinant canarypoxvirus expressing FELV genes.
Treatment indication vaccination against feline leukemia virus (FELV)
Administration route(s) subcutaneous
Total number of subjects foreseen 800
Foreseen duration of release 8 months
Effective year(s) of release not communicated
Current status Trial completed
Locations Heverlee, Deurne, Merksem, Tournai, Haine St Pierre, Ternat, Boncelles, Beaufays, Mechelen, Alleur
Number of sites 10
Monitoring
Type of procedure Classical procedure - Art. 9§1 of Royal Decree of 18 December 1998
Notes Same genetically modified virus as for dossier B/BE/97/VW9 authorized in 1998
Other

Information for the public

Information related to the decision procedure

Guidelines

Other useful information